• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CFO and CBO Laumas Sandeep

    9/23/24 1:12:01 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TIL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Laumas Sandeep

    (Last) (First) (Middle)
    C/O INSTIL BIO, INC.
    3963 MAPLE AVENUE, SUITE 350

    (Street)
    DALLAS TX 75219

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Instil Bio, Inc. [ TIL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CFO and CBO
    3. Date of Earliest Transaction (Month/Day/Year)
    09/18/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $66.1 09/18/2024 A 45,000 (1) 09/17/2034 Common Stock 45,000 $0 45,000 D
    Explanation of Responses:
    1. Twenty-five percent (25%) of the shares subject to the option vest on September 18, 2025, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
    Remarks:
    /s/ Sandeep Laumas, M.D. 09/23/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TIL

    DatePrice TargetRatingAnalyst
    1/7/2025$11.00 → $52.00Hold → Buy
    Jefferies
    1/7/2025$11.00 → $52.00Hold → Buy
    Truist
    11/4/2024Mkt Perform
    JMP Securities
    4/12/2024$5.00 → $11.00Buy → Hold
    Jefferies
    11/1/2022$16.00 → $6.00Buy → Hold
    Truist
    11/1/2022Outperform → Market Perform
    Cowen
    8/13/2021$34.00Outperform
    Robert W. Baird
    8/13/2021$34.00Outperform
    Baird
    More analyst ratings

    $TIL
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Instil Bio Inc.

      DEFR14A - Instil Bio, Inc. (0001789769) (Filer)

      5/2/25 5:00:20 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Instil Bio Inc.

      DEFA14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Instil Bio Inc.

      DEF 14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:08 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM2510 and chemotherapy by ImmuneOnco in China anticipated to begin in Q2 2025 with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, March 04, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("I

      3/4/25 7:09:26 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

      ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025 Instil is targeting initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in 2H 2025, assuming necessary regulatory approvals DALLAS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceutica

      1/14/25 7:00:37 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a

      11/13/24 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Leadership Updates

    Live Leadership Updates

    See more

    $TIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("

      11/14/22 4:07:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

      DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi

      9/6/22 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:55 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio upgraded by Truist with a new price target

      Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:34 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Instil Bio

      JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform

      11/4/24 7:41:54 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 6:59:16 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 5:48:56 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      10/25/24 9:42:03 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:42 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO and Chairman Crouch Bronson

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:15 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      9/23/24 1:12:01 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care